Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms
Who is this study for? Adult patients with stroke, aneurysm, vasculitis, and tumor necrosis factor-alpha
What treatments are being studied? Infliximab
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
Patients harboring dolichoectactic vertebrobasilar (DVB) aneurysms are at risk of suffering SAH, ischemic stroke, and/or brainstem compression and many patients are not offered invasive treatment due to the futility of existing surgical methods. Consequently, there is demand for development of medical therapy for DVB aneurysms
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Vertebral and/or basilar artery dolichoectactic aneurysm not amenable to microsurgical or endovascular treatment.
• Age greater than 18 years at time of first study drug administration.
Locations
United States
California
UCSF Medical Center
RECRUITING
San Francisco
Contact Information
Primary
Daniel L Cooke, MD
daniel.cooke@ucsf.edu
415 353 1863
Backup
Jonathan Graf, MD
jonathan.graf@ucsf.edu
415 206 6647
Time Frame
Start Date: 2024-10-01
Estimated Completion Date: 2027-12
Participants
Target number of participants: 8
Treatments
Experimental: Infliximab treatment
Administer infliximab intravenously to patients with DVB aneurysms (3 mg/kg at 0, 3 and 7 weeks, then at 8-week intervals x 7) for a total of 12-months. Patients will undergo MR imaging at 0, 12, and 24-month time points.
Related Therapeutic Areas
Sponsors
Leads: University of California, San Francisco